{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:50:48Z","timestamp":1793393448562,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.molmed.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T20:09:29Z","timestamp":1780949369000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Foxp3+ Tregs in HCC immunity and immunotherapy"],"prefix":"10.1016","author":[{"given":"Mei","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0637-739X","authenticated-orcid":false,"given":"Alessandro","family":"Granito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2026.05.004_bb0005","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2026.05.004_bb0010","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2026.05.004_bb0015","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1080\/1744666X.2025.2568904","article-title":"Immunology, immunotherapy, and the tumor microenvironment in hepatocellular carcinoma: a comprehensive review","volume":"21","author":"Akabane","year":"2025","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41577-025-01211-z","article-title":"Linking tumour angiogenesis and tumour immunity","volume":"26","author":"Kabir","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0030","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0035","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.05.004_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.609891","article-title":"Targeted de-methylation of the FOXP3-TSDR is sufficient to induce physiological FOXP3 expression but not a functional Treg phenotype","volume":"11","author":"Kressler","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0045","doi-asserted-by":"crossref","DOI":"10.1172\/JCI202216","article-title":"The 2025 Nobel Prize in Physiology or Medicine\u2014a bridge to peripheral immune tolerance","volume":"135","author":"Bluestone","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2026.05.004_bb0050","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0055","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/jimmunol\/198.3.993","article-title":"Pillars article: an essential role for scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 2003. 4: 337\u2013342","volume":"198","author":"Khattri","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0060","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0065","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41575-023-00821-z","article-title":"Friend or foe? The elusive role of hepatic stellate cells in liver cancer","volume":"20","author":"Cogliati","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0070","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and dynamics of single immune cells in hepatocellular carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.05.004_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1431211","article-title":"Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy","volume":"15","author":"Du","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0080","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cell.2020.11.041","article-title":"Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma","volume":"184","author":"Sun","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.05.004_bb0085","article-title":"SOX12 facilitates hepatocellular carcinoma progression and metastasis through promoting regulatory T-cells infiltration and immunosuppression","volume":"11","author":"Luo","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.molmed.2026.05.004_bb0090","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.05.004_bb0095","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12885-025-13435-2","article-title":"TGF-\u03b2 signaling orchestrates cancer-associated fibroblasts in the tumor microenvironment of human hepatocellular carcinoma: unveiling insights and clinical significance","volume":"25","author":"Ge","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.molmed.2026.05.004_bb0100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2019.08.016","article-title":"Gut microbiome in HCC\u2014mechanisms, diagnosis and therapy","volume":"72","author":"Schwabe","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0105","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature12721","article-title":"Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells","volume":"504","author":"Furusawa","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.05.004_bb0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.05.004_bb0115","article-title":"Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in HCC","author":"Huang","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2026.05.004_bb0120","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cell.2025.11.034","article-title":"Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity","volume":"189","author":"Gu","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.05.004_bb0125","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175897","article-title":"Lactate supports Treg function and immune balance via MGAT1 effects on N-glycosylation in the mitochondria","volume":"134","author":"Zhou","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2026.05.004_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110986","article-title":"Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-\u03b2 signaling in regulatory T cells","volume":"39","author":"Gu","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.molmed.2026.05.004_bb0135","article-title":"CXCL12\/CXCR4 axis governs Treg spatial dominance over CD8+ T cells via IL-2 sequestration: a dual therapeutic target in prostate cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0140","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79342","article-title":"Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2","volume":"12","author":"Tsyklauri","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.molmed.2026.05.004_bb0145","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1038\/s41467-025-60082-z","article-title":"Expression of an interleukin-2 partial agonist enhances regulatory T cell persistence and efficacy in mouse autoimmune models","volume":"16","author":"Robert","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2026.05.004_bb0150","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240445","article-title":"Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39","volume":"222","author":"Tan","year":"2025","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2026.05.004_bb0155","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73699","article-title":"Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors","volume":"11","author":"Chambers","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.molmed.2026.05.004_bb0160","article-title":"Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers","volume":"6","author":"Myojin","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.molmed.2026.05.004_bb0165","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/s41388-025-03330-2","article-title":"Integrated single-cell and spatial transcriptomic profiling reveals that CD177+ Tregs enhance immunosuppression through apoptosis and resistance to immunotherapy in hepatocellular carcinoma","volume":"44","author":"Liang","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2026.05.004_bb0170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12967-023-04104-8","article-title":"Blockade of CCR4 breaks immune tolerance in chronic hepatitis B patients by modulating regulatory pathways","volume":"21","author":"Khanam","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.molmed.2026.05.004_bb0175","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2021.08.029","article-title":"Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B","volume":"76","author":"Gao","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0180","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2026.05.004_bb0185","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2020.08.040","article-title":"Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma","volume":"183","author":"Sharma","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2026.05.004_bb0190","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41698-024-00564-3","article-title":"Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma","volume":"8","author":"Fan","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0195","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg3750","article-title":"Comprehensive analysis of spatial architecture in primary liver cancer","volume":"7","author":"Wu","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2026.05.004_bb0200","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0205","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","article-title":"Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer","volume":"36","author":"Ma","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2026.05.004_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1735189","article-title":"Neutrophils in the hepatocellular carcinoma microenvironment: orchestrators of progression and immunity","volume":"17","author":"Lian","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0215","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jhep.2022.03.011","article-title":"Blocking CD47 promotes antitumour immunity through CD103+ dendritic cell-NK cell axis in murine hepatocellular carcinoma model","volume":"77","author":"Wang","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0220","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s44466-025-00021-1","article-title":"Mechanistic understanding of crosstalk between blood vessels and immunity and inflammation in diseases","volume":"2","author":"Cao","year":"2026","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.molmed.2026.05.004_bb0225","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","article-title":"TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma","volume":"79","author":"Tan","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0230","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41577-020-0376-4","article-title":"Targeting CD39 in cancer","volume":"20","author":"Moesta","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0235","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.molmed.2026.05.004_bb0240","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2025.10.017","article-title":"The role of liver sinusoidal endothelial cells in liver diseases: key players in health and pathology","volume":"84","author":"Felli","year":"2026","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0245","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41568-021-00383-9","article-title":"The immunological and metabolic landscape in primary and metastatic liver cancer","volume":"21","author":"Li","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.molmed.2026.05.004_bb0250","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","volume":"22","author":"Seyhan","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0255","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.3748\/wjg.v27.i22.2994","article-title":"Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment","volume":"27","author":"Granito","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0260","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.immuni.2022.10.006","article-title":"Regulatory T cells as metabolic sensors","volume":"55","author":"de Candia","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.molmed.2026.05.004_bb0265","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","article-title":"Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments","volume":"25","author":"Angelin","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2026.05.004_bb0270","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.gastro.2015.03.004","article-title":"Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function","volume":"149","author":"Serti","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2026.05.004_bb0275","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jhep.2024.06.011","article-title":"Epigenetic scars in regulatory T cells are retained after successful treatment of chronic hepatitis C with direct-acting antivirals","volume":"81","author":"Kim","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0280","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0285","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s10238-025-01851-4","article-title":"HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications","volume":"26","author":"Shen","year":"2026","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.molmed.2026.05.004_bb0290","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2026.05.004_bb0295","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/apt.17818","article-title":"Editorial: how does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure?","volume":"59","author":"Innes","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2026.05.004_bb0300","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jhep.2018.10.023","article-title":"Inflammatory pathways in alcoholic steatohepatitis","volume":"70","author":"Gao","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128347","article-title":"Prognostic significance of the systemic inflammatory and immune balance in alcoholic liver disease with a focus on gender-related differences","volume":"10","author":"Kasztelan-Szczerbi\u0144ska","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2026.05.004_bb0310","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/acer.12095","article-title":"Decreased peripheral blood CD4+\/CD25+ regulatory T cells in patients with alcoholic hepatitis","volume":"37","author":"Almeida","year":"2013","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.molmed.2026.05.004_bb0315","article-title":"The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0320","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ni.2386","article-title":"Metabolic checkpoints in activated T cells","volume":"13","author":"Wang","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0325","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.gastro.2020.09.031","article-title":"Steatohepatitis impairs T-cell\u2013directed immunotherapies against liver tumors in mice","volume":"160","author":"Heinrich","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2026.05.004_bb0330","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.05.004_bb0335","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","article-title":"CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors","volume":"21","author":"Wang","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102619","article-title":"Regulatory T cells in autoimmune hepatitis: an updated overview","volume":"119","author":"Longhi","year":"2021","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.molmed.2026.05.004_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103806","article-title":"Role of regulatory T cells in inflammatory liver diseases","volume":"24","author":"Yang","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.molmed.2026.05.004_bb0350","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/cancers13051023","article-title":"Current trends and characteristics of hepatocellular carcinoma in patients with autoimmune liver diseases","volume":"13","author":"Rigopoulou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.molmed.2026.05.004_bb0355","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ueg2.12238","article-title":"The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: a Swedish nationwide population-based cohort study","volume":"10","author":"Bengtsson","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.molmed.2026.05.004_bb0360","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1055\/s-0043-1776127","article-title":"Unraveling the complexities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"43","author":"Han","year":"2023","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.molmed.2026.05.004_bb0365","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0370","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ccell.2018.05.005","article-title":"Selective Fc\u03b3R co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens","volume":"33","author":"Waight","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.molmed.2026.05.004_bb0375","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.molmed.2026.05.004_bb0380","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/14737140.2023.2181162","article-title":"TKIs in combination with immunotherapy for hepatocellular carcinoma","volume":"23","author":"Stefanini","year":"2023","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.molmed.2026.05.004_bb0385","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1073\/pnas.1902145116","article-title":"Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy","volume":"117","author":"Kashyap","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2026.05.004_bb0390","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0395","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2026.05.004_bb0400","article-title":"Peripheral blood Foxp3-high Tregs: a novel prognostic biomarker in hepatocellular carcinoma","author":"Su","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2026.05.004_bb0405","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2026.05.004_bb0410","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1186\/s12885-021-08363-w","article-title":"Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.molmed.2026.05.004_bb0415","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/1078-0432.CCR-21-2781","article-title":"Mogamulizumab in combination with nivolumab in a phase I\/II study of patients with locally advanced or metastatic solid tumors","volume":"28","author":"Hong","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2026.05.004_bb0420","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/hep.31466","article-title":"Transcriptome profiling identifies TIGIT as a marker of T-cell exhaustion in liver cancer","volume":"73","author":"Ostroumov","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2026.05.004_bb0425","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2026.05.004_bb0430","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41419-025-07984-4","article-title":"TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies","volume":"16","author":"Cui","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.molmed.2026.05.004_bb0435","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa1983","article-title":"Monoclonal antibodies against GARP\/TGF-\u03b21 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo","volume":"7","author":"Cuende","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2026.05.004_bb0440","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1126\/science.aau2909","article-title":"Structural basis of latent TGF-\u03b21 presentation and activation by GARP on human regulatory T cells","volume":"362","author":"Lienart","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.molmed.2026.05.004_bb0445","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.it.2023.06.001","article-title":"Targeting the metabolism of tumor-infiltrating regulatory T cells","volume":"44","author":"Wang","year":"2023","journal-title":"Trends Immunol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0450","article-title":"Puerarin targets MIC19 to suppress mitochondrial metabolism of tumor-infiltrating Tregs and enhance anti-tumor immunity","volume":"13","author":"Li","year":"2026","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.molmed.2026.05.004_bb0455","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1038\/s41388-025-03593-9","article-title":"PSME3 drives Tregs infiltration and anti-PD1 resistance in hepatocellular carcinoma by regulating FBXL7\/PTEN-mediated metabolic reprogramming","volume":"44","author":"Chen","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.molmed.2026.05.004_bb0460","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41419-025-07544-w","article-title":"Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application","volume":"16","author":"Pan","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.molmed.2026.05.004_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103046","article-title":"CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation","volume":"141","author":"Elahi","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.molmed.2026.05.004_bb0470","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.2147\/IJN.S527315","article-title":"Nanomaterials mediated enhancement of CAR-T for HCC: revolutionizing immunotherapy strategies","volume":"20","author":"Liu","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.molmed.2026.05.004_bb0475","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2018.05.018","article-title":"Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy","volume":"281","author":"Ou","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.molmed.2026.05.004_bb0480","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2026.05.004_bb0485","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","article-title":"Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges","volume":"17","author":"Martin","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0490","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nmat3792","article-title":"Strategies for advancing cancer nanomedicine","volume":"12","author":"Chauhan","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.molmed.2026.05.004_bb0495","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20182232","article-title":"PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance","volume":"218","author":"Tan","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2026.05.004_bb0500","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.molmed.2026.05.004_bb0505","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2026.05.004_bb0510","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0515","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/1750743X.2025.2549675","article-title":"Pure red cell aplasia due to Parvovirus B19 infection and atezolizumab: case report and literature review","volume":"17","author":"Pallotta","year":"2025","journal-title":"Immunotherapy"},{"key":"10.1016\/j.molmed.2026.05.004_bb0520","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2026.05.004_bb0525","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001749","article-title":"Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy","volume":"9","author":"Van Damme","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.molmed.2026.05.004_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2026.150512","article-title":"Next-generation therapies for hepatocellular carcinoma: CAR-T cell and anticancer peptide synergy","volume":"344","author":"Kannan","year":"2026","journal-title":"Int. J. Biol. Macromol."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491426001139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491426001139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T20:09:42Z","timestamp":1780949382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491426001139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":106,"alternative-id":["S1471491426001139"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2026.05.004","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Foxp3+ Tregs in HCC immunity and immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}